Darzalex Faspro Approved by the U.S. FDA for Patients with High-Risk Smoldering Multiple Myeloma

Nov 7, 2025 - 14:00
 0  1
Horsham, PA., November 6, 2025 – Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients with...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0